Natalizumab Versus Fingolimod and Dimethyl Fumarate in Multiple Sclerosis Treatment

Annals of Clinical and Translational Neurology - United States
doi 10.1002/acn3.700
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Comparison of Fingolimod and Dimethyl Fumarate in the Treatment of Multiple Sclerosis: Two-Year Experience

Multiple Sclerosis Journal – Experimental, Translational and Clinical
2017English

HDL-cholesterol Elevation Associated With Fingolimod and Dimethyl Fumarate Therapies in Multiple Sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical
2019English

Dimethyl Fumarate Treatment Alters NK Cell Function in Multiple Sclerosis

European Journal of Immunology
AllergyImmunology
2017English

Dimethyl Fumarate for Relapsingremitting Multiple Sclerosis

Prescriber
Pharmacology
2014English

Natalizumab Treatment in Multiple Sclerosis

Clinical Neurology
Neurology
2015English

Predictors for Multiple Sclerosis Relapses After Switching From Natalizumab to Fingolimod

Multiple Sclerosis
Neurology
2014English

Efficacy of Natalizumab and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting

Journal of Neurology & Neurophysiology
2015English

Tumefactive Multiple Sclerosis Lesions Under Fingolimod Treatment

Neurology
Neurology
2012English

Correction To: Switching From Natalizumab to Fingolimod Treatment in Multiple Sclerosis: Real Life Data From the Austrian MS Treatment Registry

Journal of Neurology
Neurology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy